Abstract
A special questionnaire was used to evaluate the therapy compliance in patients who were observed in primary health institutions according to inhabitation and present medical recommendations based on scientifically proved facts ("evidence-based medicine"). We revealed low monitoring level in the outpatient setting, insufficient pharmacotherapy with ACE-inhibitors, beta-blockers, statins, and absence of non-pharmacological treatment in management of these patients.
References
1. Бенделиани, Н. Г. Влияние оптимизированной многофакторной программы лечения больных с выраженной хронической сердечной недостаточностью на качество их жизни: автореф. дис.
2. Бокерия, Л. А. Потребность в хирургических и эндоваскулярных методах лечения при ишемической болезни сердца /Л. А. Бокерия, И. Н. Ступаков, И. В. Самородская и др. // Мед. вестн. - 2008. - № 34 (461). - С. 3.
3. Бокерия, Л. А. Роль системы здравоохранения и гражданского общества в обеспечении профилактики сердечно-сосудистых заболеваний / Л. А. Бокерия // Тезисы доклада конференции "Профилактика, лечение и реабилитация болезней сердца и сосудов" - М., 2007. - С. 7.
4. Гиляревский, С. Р. Терапевтическое обучение больных с хронической сердечной недостаточностью: методические вопросы и практическое применение / С. Р. Гиляревский, В. А. Орлов, О. А. Боева и соавт. // Рос. кардиол. журн. - 2000. - № 5. - С. 64-69
5. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major Outcomes in Moderately Hypercholesterolemic., Hypertensive Patients Randomized to Pravastatin vs Usual Care: The Antyh and ypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT) // JAMA. - 2002; 2008. - P. 2998-3007.
6. Anderson, R. T. Issues of aging and adherence to health interventions / R. T. Anderson, M. Ory, S. Cohen, J. S. McBride // Control. Clin. Trials. - 2000. - Vol. 5. - P. S171-S18 (Suppl. 1).
7. Arnold, P. Diabetes patient education / P. Arnold, C. Stepka-Tracey, D. Zheng et al. // J. S. C. Med. Assoc. - 1998. - Vol. 94, № 11. - P. 478-484.
8. Bonow, R. O. Guidelines for the Management of Patients With Valvular Heart Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Patients With Valvular Heart Disease) / R. O. Bonow, В. Carabello, A. C. de Leon et al. // Circulation. - 1998. - Vol. 98. - P. 1949-1984.
9. Bouhour, J. B. Education des patients insuffisants cardiaques / J. B. Bouhour // Arch. Mal. Coeur Vaiss. - 1998. - Vol. 91, № 11. - P. 1407-1410.
10. Canno, C. P. Intensive versus moderate lipid-lowering with statins after acute coronary syndromes / C.P. Cannon, E. Braunwald, C. H. McCabe et al.// N. Engl. J. Med. - 2004. - Vol. 350, № 15. - P. 1495-1504.
11. EUROASPIRE Study Group. EUROASPIRE: a European Society of Cardiology survey of secondary prevention of coronary heart disease, principal results / EUROASPIRE Study Group // Eur. Heart J. - 1997. - Vol. 18. - P. 1569-1582
12. EUROASPIRE II Group. Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries: principal results from EUROASPIRE II / EUROASPIRE II Group // Eur. Heart J. - 2001. - Vol. 22. - P. 554-572.
13. Gibbons, R. J. ACC/AHA/ACP-ASIM Guidelines for the Management of Patients With Chronic Stable Angina: Executive Summary and Recommendations: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Patients With Chronic Stable Angina) / R. J. Gibbons, К. Chatterjee, J. Daley et al. // Circulation. - 1999. - Vol. 99, № 21. - P. 2829-2848.
14. Grundy, S. M. Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines / S. M. Grundy, Cleeman, C. N. B. Merz // Circulation. - 2004.- Vol. 10. - P. 227-239.
15. Michalsen, A. Preventable causative factors leading to hospital admission with decompensated heart failure / A. Michalsen, G. Kцnig, W. Thimme // Heart. - 1998. - Vol. 80. - P. 437-441.
16. MRS/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20.536 high-risk individuals: a randomized placebo-controlled trial // Lancet. - 2002. - Vol. 360. - P. 7-22.
17. Nissen, S. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial / S. Nissen, S. J. Nicholls, I. Sipahi et al. // JAMA. - 2006. - Vol. 295, № 13. - P. 1556-1565.
18. Nissen, S. E. for REVERSAL Investigators. Statin Therapy, LDL Cholesterol, C-Reactive Protein, and Coronary Artery Disease / S. E. Nissen, E. Tuzcu, P. Schoenhagen et al. // N. Engl. J. Med. - 2005. - Vol. 352, № 1. - P. 29-38.
19. Nodhturft, V. Chronic disease self-management: improving health outcomes / V. Nodhturft, J. M. Schneider, P. Hebert et al. // Nurs. Clin. North. Amer. - 2000. - Vol. 35, № 2. - P. 507-518.
20. Ridker, P. M. for PROVT IT-TIMI 22 Integrators. C-reactive protein levels outcomes after statin therapy / P. M. Ridker, C. P. Cannot et al. // N. Engl. J. Med. - 2005. - Vol. 352, № 1. - P. 20-28.
21. Sever, P. S. ASCOT investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower than average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial Lipid Lowering Arm. (ASCOT - LLA): a multicentre controlled lipid-lowering trial / P. S. Sever, B. Dahlof, N. R. Poulter et al. // Lancet. - 2003. - Vol. 361 (9364). - P. 1149-1158.
22. Shepherd, J. PROSPER Study Group. Pravastatin in Elderly individuals at risk / J. Shepherd, G. J. Blauw, M. B. Murphy et al. // Lancet. - 2002. - Vol. 360 (9346). - P. 1623-1630.
23. Sudre, P. Objectives, methods and content of patient education programmes for adults with asthma: systematic review of studies published between 1979 and 1998 / P. Sudre, S. Jacquemet, C. Uldry, T. V. Perneger // Thorax. - 1999. - Vol. 54, № 8. - P. 681-687.
24. Velazquez E. J. Valsartan In Acute myocardial Infarction (VALIANT) trial: baseline characteristics in context / E. J. Velazquez, M. A. Pfeffer, J. V. McMurray et al. // Eur. J. Heart Fail. - 2003. - Vol. 5. - P. 537-544.
25. Wood, D. A. Clinical reality of coronary prevention guidelines: comparison of EUROASPIRE I and II in nine countries / D. A. Wood, EUROASPIRE I and II Group // Lancet.-2001.-Vol. 357(9261).- P. 995-1001.
